# Ipamorelin CJC-1295: Research on the Combined Peptide Stack

> Ipamorelin CJC-1295: what the research shows about combining GHS-R1a and GHRH receptor stimulation for supraadditive pulsatile growth hormone release.

## Why the Combination Is Studied

The ipamorelin CJC-1295 combination is the highest-volume related search term in the ipamorelin keyword landscape, reflecting widespread researcher and clinician interest in the dual-peptide approach. The mechanistic basis is straightforward: ipamorelin acts at GHS-R1a (ghrelin receptor); CJC-1295 acts at GHRHR (GHRH receptor). These are distinct receptor families that converge on the same pituitary somatotroph cell [16][18][19].

Activating both pathways simultaneously — GHRH-analog signal + ghrelin-pathway signal — has been shown to produce supraadditive GH release in preclinical models compared to either agent alone. The complementary signaling mechanism (GHRHR through adenylyl cyclase and cAMP; GHS-R1a through phospholipase C and calcium mobilization) is the reason researchers study this combination rather than doubling a single-agent dose.

## Mechanism of the CJC-1295 and Ipamorelin Combination

CJC-1295 prolongs endogenous GHRH signal at the pituitary via its 5.8–8.1 day half-life in humans [12]; ipamorelin independently activates GHS-R1a. CJC-1295's GHRHR signaling elevates intracellular cAMP and activates protein kinase A; ipamorelin's GHS-R1a signaling elevates calcium through Gq/11 and phospholipase C. Both converge on GH exocytosis from somatotrophs. The dual-receptor stimulation produces GH release greater than either peptide alone in preclinical models, with ipamorelin contributing the ghrelin-pathway amplification [18][19].

## CJC-1295 Human Data

While ipamorelin has no published human GH-release data outside of the GI motility trial (where GH was not an endpoint), CJC-1295 has been studied in healthy adults. Teichman et al. (2006, PMID 16352683) conducted a Phase 1/2 trial of CJC-1295 30–60 µg/kg subcutaneous in healthy adults aged 21–61. A single injection produced dose-dependent GH increases of 2- to 10-fold for 6 or more days; mean plasma IGF-1 increased 1.5- to 3-fold and remained elevated for 9–11 days. The half-life of CJC-1295 was estimated at 5.8–8.1 days [12].

Sackmann-Sala et al. (2009) further characterized CJC-1295's downstream effects, documenting activation of the GH/IGF-1 axis and measurable changes in serum protein profiles in normal adult subjects [19]. Pulsatile GH secretion was preserved during continuous CJC-1295 receptor stimulation in animal models (Frohman and Kineman 2006), supporting the combination rationale [18].

This human CJC-1295 data does not substitute for ipamorelin-specific human GH data. It provides mechanistic context for the GHRH-pathway component of the combination.

## What Is Not Established for the Combination

No published human controlled trial has directly studied the ipamorelin + CJC-1295 combination as a regimen. The supraadditive GH-release data derives from preclinical models and the mechanistic complementarity of their receptor pharmacology [16][19]. Clinical outcome data for the combination (body composition, bone density, IGF-1 sustained response, safety) does not exist in the published peer-reviewed literature.

The CJC-1295 monotherapy human trial (Teichman 2006) provides the clearest available benchmark for what GHRH-pathway stimulation alone produces in humans [12]. Ipamorelin's contribution is documented in preclinical models. The combination's human effect profile has not been measured.

## References

[12] Teichman SL, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[16] Raun K, et al. Ipamorelin — GHS-R1a vs GHRHR receptor family distinction. Eur J Endocrinol. 1998;139(5):552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/
[18] Frohman LA, Kineman RD. Pulsatile GH secretion persists during continuous CJC-1295 stimulation. J Clin Endocrinol Metab. 2006. https://pubmed.ncbi.nlm.nih.gov/17018654/
[19] Sackmann-Sala L, et al. Activation of GH/IGF-1 axis by CJC-1295 in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471–477. https://pubmed.ncbi.nlm.nih.gov/19386527/

---

A pastel-cloud reading of the ipamorelin literature — soft pulsatile pharmacology summarized from the peer-reviewed record, held by no clinic and sold by no one.